{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T18:00:41Z","timestamp":1781632841271,"version":"3.54.5"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T00:00:00Z","timestamp":1769990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T00:00:00Z","timestamp":1772496000000},"content-version":"vor","delay-in-days":29,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ital J Pediatr"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Primary care is essential during children\u2019s development, especially in the first years of life. Contacts with the Family Pediatricians (FP) always presented with seasonality, peaking in infants and toddlers. In Italy, nirsevimab was widely introduced in November 2024, potentially influencing the pattern of pediatric care utilization. This study aimed to evaluate temporal changes in FP contacts and the burden of bronchiolitis following nirsevimab introduction.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective observational study has been conducted within Pedianet, an Italian primary-care network of FPs. Children residing in the Veneto region under five years of age and active between September 2022 and 2025 were included. All FP contacts were considered, identifying bronchiolitis-related visits and immunization ones. Age-specific incidence rates (IR) expressed in 100 person-months with 95% confidence intervals (CI) were calculated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 25,399 children (median follow-up: 20.99\u2009months) were included. Overall, 71.68 (95%CI:71.46\u201371.91) contacts per 100 person-months were recorded, showing clear seasonality with decreasing incidence while increasing age. After excluding immunization contacts, the difference in IRs between children in their first and second year of life was smaller in 2024\/2025 than in 2023\/2024, particularly in November (1-year:88.96 [95%CI:85.78\u201392.14] and 2-year:84.68 [95%CI:81.40\u201387.95] compared with 119.3 [95%CI:115.47\u2013123.12] and 94.19 [95%CI:90.72\u201397.66]). Bronchiolitis burden among infants\u2009&lt;\u20091\u2009year declined from 6.58 (95%CI:5.70\u20137.47) to 1.24 (95%CI:0.87\u20131.62) contacts per 100 person-months in January 2024 and 2025, respectively, with a delayed seasonal peak in February 2025 (IR\u2009=\u20092.00, 95%CI:1.50\u20132.50).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Following nirsevimab introduction, the burden of bronchiolitis markedly decreased, and differences in early-life contact rates narrowed. These findings support the need for adaptive pediatric care planning and continuous surveillance of respiratory disease trends accounting for preventive strategies implemented at the community level.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13052-026-02205-w","type":"journal-article","created":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T13:05:24Z","timestamp":1770037524000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Changes in pediatric primary care contacts: has the RSV-immunization modified the age-related access?"],"prefix":"10.1186","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-8339-9485","authenticated-orcid":false,"given":"Riccardo","family":"Boracchini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Barbieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedetta","family":"Canova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenio","family":"Baraldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Giaquinto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Cantarutti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,2]]},"reference":[{"key":"2205_CR1","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1111\/j.1468-0009.2005.00409.x","volume":"83","author":"B Starfield","year":"2005","unstructured":"Starfield B, Shi L, Macinko J. Contribution of primary care to health systems and health. Milbank Q. 2005;83:457\u2013502.","journal-title":"Milbank Q"},{"key":"2205_CR2","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1056\/NEJMsa064637","volume":"357","author":"R Mangione-Smith","year":"2007","unstructured":"Mangione-Smith R, DeCristofaro AH, Setodji CM, et al. The quality of ambulatory care delivered to children in the United States. N Engl J Med. 2007;357:1515\u201323.","journal-title":"N Engl J Med"},{"key":"2205_CR3","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1093\/fampra\/cmv082","volume":"33","author":"MJ van den Berg","year":"2016","unstructured":"van den Berg MJ, van Loenen T, Westert GP. Accessible and continuous primary care may help reduce rates of emergency department use. An international survey in 34 countries. Fam Pract. 2016;33:42\u201350.","journal-title":"Fam Pract"},{"key":"2205_CR4","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1186\/s12887-023-04005-1","volume":"23","author":"M Moser","year":"2023","unstructured":"Moser M, M\u00fcllner C, Ferro P, Albermann K, Jenni OG, von Rhein M. The role of well-child visits in detecting developmental delay in preschool children. BMC Pediatr. 2023;23:180.","journal-title":"BMC Pediatr"},{"key":"2205_CR5","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1186\/s13052-024-01754-2","volume":"50","author":"R Boracchini","year":"2024","unstructured":"Boracchini R, Canova B, Ferrara P, et al. A silent strain: the unseen burden of acute respiratory infections in children. Ital J Pediatr. 2024;50:167.","journal-title":"Ital J Pediatr"},{"key":"2205_CR6","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1016\/S0140-6736(17)30938-8","volume":"390","author":"T Shi","year":"2017","unstructured":"Shi T, McAllister DA, O\u2019Brien KL, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. Lancet. 2017;390:946\u201358.","journal-title":"Lancet"},{"key":"2205_CR7","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1056\/NEJMoa2309189","volume":"389","author":"SB Drysdale","year":"2023","unstructured":"Drysdale SB, Cathie K, Flamein F, et al. Nirsevimab for Prevention of hospitalizations due to RSV in infants. N Engl J Med. 2023;389:2425\u201335.","journal-title":"N Engl J Med"},{"key":"2205_CR8","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1056\/NEJMoa2110275","volume":"386","author":"LL Hammitt","year":"2022","unstructured":"Hammitt LL, Dagan R, Yuan Y, et al. Nirsevimab for Prevention of RSV in healthy late-preterm and term infants. N Engl J Med. 2022;386:837\u201346.","journal-title":"N Engl J Med"},{"key":"2205_CR9","doi-asserted-by":"publisher","unstructured":"L\u00f3pez-Lacort M, Mu\u00f1oz-Quiles C, Mira-Iglesias A, et al. Nirsevimab effectiveness against severe respiratory syncytial virus infection in the primary care setting. Pediatrics. 2025;155. https:\/\/doi.org\/10.1542\/peds.2024-066393.","DOI":"10.1542\/peds.2024-066393"},{"key":"2205_CR10","doi-asserted-by":"publisher","first-page":"e250380","DOI":"10.1001\/jamanetworkopen.2025.0380","volume":"8","author":"H Xu","year":"2025","unstructured":"Xu H, Aparicio C, Wats A, et al. Estimated effectiveness of nirsevimab against respiratory syncytial virus. JAMA Netw Open. 2025;8:e250380.","journal-title":"JAMA Netw Open"},{"key":"2205_CR11","first-page":"E172","volume":"65","author":"A Orsi","year":"2024","unstructured":"Orsi A, Scarpaleggia M, Baldo V, et al. First real-world data on universal respiratory syncytial virus prophylaxis with nirsevimab in infants. J Prev Med Hyg. 2024;65:E172\u201387.","journal-title":"J Prev Med Hyg"},{"key":"2205_CR12","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1111\/apa.70066","volume":"114","author":"JM Rius-Peris","year":"2025","unstructured":"Rius-Peris JM, Palomo-Atance E, Muro-D\u00edaz E, Llorente-Ruiz C, Murcia-Clemente L, Alcaraz R. Nirsevimab immunisation significantly reduces respiratory syncytial virus-associated bronchiolitis hospitalisations and alters seasonal patterns. Acta Paediatr. 2025;114:1963\u201376.","journal-title":"Acta Paediatr"}],"container-title":["Italian Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13052-026-02205-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13052-026-02205-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13052-026-02205-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T17:49:56Z","timestamp":1781632196000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13052-026-02205-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,2]]},"references-count":12,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2205"],"URL":"https:\/\/doi.org\/10.1186\/s13052-026-02205-w","relation":{},"ISSN":["1824-7288"],"issn-type":[{"value":"1824-7288","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,2]]},"assertion":[{"value":"12 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This is an observational, retrospective, non-interventional study. According to a bylaw on the classification and implementation of observational drug-related research, as issued by the Italian National Drug Agency (an entity belonging to the Italian Ministry of Health), this study does not require approval by an ethics committee in Italy (Italian Drug Agency note on August 3, 2007). This study was conducted in accordance with the tenets of the Declaration of Helsinki and was compliant with the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance\u2019s Guide on Methodological Standards in Pharmacoepidemiology. Written informed consent to participate in this study was provided by the participants\u2019 legal guardian\/next of kin.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The study and access to the database was approved by the Internal Scientific Committee of So.Se.Te. Srl, the legal owner of Pedianet. The corresponding author confirm that he had full access to all the data in the study and had final responsibility for the decision to submit for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that the research was conducted without commercial or financial relationships that could be construed as potential conflicts of interest. The authors have no conflict of interest to declare. We affirm that this manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned (and, if relevant, registered) have been explained. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of any organization or company.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"32"}}